 |
 |
 |
 |
 |
 |
 |
 |
 |
Experimed
Experimed spun off from Trellis Bioscience in order to leverage the parent company’s proprietary CellSpot™ technology outside Trellis’ area of focus (therapeutic antibodies). This technology seeks to enable a qualitatively new approach to the detection of rare events within a cell population through the convergence of proprietary assay multiplexing and miniaturization technologies.